News for ALK-Abelló A/S (AKABY)

**media[645888]**

Revenue: Achieved $8.0 million in total revenue for Q1 2025, surpassing the estimated $7.48 million.Net Product Revenue: Generated $7.8 million from U.S. sales

**media[625363]**

ALK-Abelló A/S (OTCPK:AKBLF) Q1 2025 Earnings Conference Call May 6, 2025 5:00 AM ETCompany ParticipantsPer Plotnikof - Head of IRPeter Halling - CEOClaus...

The following slide deck was published by ALK-Abelló A/S in conjunction with their 2025 Q1 earnings call.

**media[619343]**

**media[615396]**

ARS Pharmaceuticals (NASDAQ:SPRY) partners with ALK to co-promote neffy, an epinephrine nasal spray, to 9,000 pediatricians. Read more here.

**media[612727]**

**media[609244]**

**media[603319]**

**media[585319]**

$7.3 million in total neffy® (epinephrine nasal spray) U.S. net product revenue in 2024 since launch in late September 2024 neffy 1 mg approved by U.S. FDA fo

**media[566006]**

**media[557385]**

**media[546750]**

ALK-Abelló A/S (OTCPK:AKBLF) Q4 2024 Results Conference Call February 19, 2025 7:30 AM ETCompany ParticipantsPer Plotnikof - Head of IRPeter Halling -...

ALK-Abelló A/S FY results: Revenue grew 15% to DKK 5.5B, driven by 24% tablet sales growth. European market momentum boosted performance.

**media[543948]**